ClinicalTrials.gg
RecruitingNCT06654752STOP PEDS RCTUpdated Nov 19, 2026

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

An interventional study of Immediate Oral Antibiotics and Tailored Treatment: Oral Antibiotics only if Additional Treatment needed in Cystic Fibrosis, sponsored by University of Washington, the Collaborative Health Studies Coordinating Center. Recruiting at 33 sites in 2 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Washington, the Collaborative Health Studies Coordinating Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
24th of 517
430 · median 36
Started
2024
with 29 others
No phase
155 of 717
17 open now
Primary completion
2027-12
later than 68 of 108 live
Registered
682nd of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 24th largest by planned enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 155 with no phase, reaches primary completion later than 68 of the 108 other live ones, and was the 682nd registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

Read the detailed description

The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.

Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.

The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.

Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:

  • Clinic throat swab substudy
  • Home throat and nasal swab substudy
  • Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)
03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • cystic fibrosis
  • oral antibiotics
  • pulmonary exacerbation
  • pediatric
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age

    1. For main cohort and non-HEMT cohort: age 6 to \<19 years
    2. For preschool cohort: age 3 to \<6 years
  2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

    1. sweat chloride ≥ 60 mEq/liter
    2. two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
  3. Written (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
  4. Highly Effective Modulator Therapy

    1. For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
    2. For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
  5. For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
  6. For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
  7. Ability to receive text messages and access the internet

Exclusion criteria

Exclusion Criteria:

  1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
  2. Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
  3. Treatment with systemic at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
  4. History of solid organ transplant
  5. History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
  6. Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
  7. Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
  8. Treatment with chronic oral antibiotics other than azithromycin at enrollment
  9. Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Immediate Antibiotics

    Increased airway clearance plus early initiation of oral antibiotics

    Other: Immediate Oral Antibiotics

  • Experimental
    Tailored Therapy

    Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve

    Other: Tailored Treatment: Oral Antibiotics only if Additional Treatment needed

Interventions

  • OtherImmediate Oral Antibiotics

    Increase airway clearance and start 14 days of preselected oral antibiotics right away

  • OtherTailored Treatment: Oral Antibiotics only if Additional Treatment needed

    Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria

06

What researchers measure

Primary outcomes

  1. One-year change in pulmonary function by spirometry-measured ppFEV1

    Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.

    Time frame: 1 year

Secondary outcomes

  1. One-Year change in pulmonary function by LCI

    Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level.

    Time frame: 1 year

Other outcomes

  1. Recovery to baseline by ppFEV1 and CRISS following a PEx

    Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 28 days

  2. Recovery to baseline by Lung Clearance Index (LCI)

    Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 28 days

  3. Safety Endpoint 1: Cumulative oral antibiotic exposure

    Compare cumulative oral antibiotic exposure in each treatment arm.

    Time frame: 1 year

  4. Safety Endpoint 2: Number of respiratory illnesses

    Compare the number of respiratory illnesses reported over the study period in each treatment arm.

    Time frame: 1 year

  5. Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx

    Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm.

    Time frame: 28 days

  6. Safety Endpoint 4: Number of PEx treated with IV antibiotics

    Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm.

    Time frame: 1 year

  7. Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28

    Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm.

    Time frame: 28 days

  8. Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28

    Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm.

    Time frame: 1 year

  9. Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness

    Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm.

    Time frame: 1 year

  10. Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)

    Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm.

    Time frame: 1 year

  11. Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures

    Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm.

    Time frame: 1 year

  12. Qualitative Assessment 1: Caregivers' experience managing study treatment

    To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences.

    Time frame: 1 year

  13. Qualitative Assessment 2: Study treatment impact on child and family daily life

    To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences.

    Time frame: 1 year

  14. Health care costs 1: Total estimated cost of antibiotics

    Compare total estimated cost of antibiotics used over the course of the study between treatment arms.

    Time frame: 1 year

  15. Health care costs 2: Health care utilization

    Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits.

    Time frame: 1 year

  16. Health care costs 3: Parent work productivity measures (WPAI)

    To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment.

    Time frame: 1 year

  17. Preschool and non-HEMT Pilot Cohort Primary Feasibility

    Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx).

    Time frame: 28 days

  18. Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery

    Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms.

    Time frame: 28 days

  19. Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery

    Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 28 days

  20. Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events

    Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms.

    Time frame: 28 days

  21. Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms

    Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms.

    Time frame: 28 days

  22. Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics

    Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms.

    Time frame: 28 days

  23. Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx

    Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms.

    Time frame: 28 days

  24. Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1

    Measure the proportion of approached patients that enrolls.

    Time frame: 28 days

  25. Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2

    Measure the proportion of respiratory symptoms meeting randomization criteria.

    Time frame: 28 days

  26. Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3

    Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm.

    Time frame: 28 days

  27. Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4

    Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm.

    Time frame: 28 days

  28. Clinic Throat Swab Substudy 1: Metagenomic Sequencing

    Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms.

    Time frame: 1 year

  29. Clinic Throat Swab Substudy 2: Microbiota Measures

    Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments.

    Time frame: 1 year

  30. Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency

    Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis.

    Time frame: 28 days

  31. Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing

    Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx).

    Time frame: 28 days

  32. Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery

    Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 28 days

  33. Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1

    Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28.

    Time frame: 28 days

  34. Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.

    Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment.

    Time frame: 28 days

  35. Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes

    Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy.

    Time frame: 28 days

  36. Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx

    Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study.

    Time frame: 28 days

  37. Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx

    Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study.

    Time frame: 14 days

  38. Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry

    Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28).

    Time frame: 28 days

  39. Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures

    Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state.

    Time frame: 28 days

  40. Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx

    Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state.

    Time frame: 14 days

  41. Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx

    Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state.

    Time frame: 14 days

  42. Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx

    Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state.

    Time frame: 14 days

  43. Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx

    Describe changes in sleep time from Day 0 to 14 of the exacerbation state.

    Time frame: 14 days

  44. Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages

    Compare changes in resting HR to averages from a 7-day period during baseline state.

    Time frame: 14 days

  45. Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages

    Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state.

    Time frame: 14 days

  46. Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages

    Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state.

    Time frame: 14 days

  47. Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages

    Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state.

    Time frame: 14 days

  48. Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)

    Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 14 days

  49. Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate

    Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 14 days

  50. Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level

    Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 14 days

  51. Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration

    Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

    Time frame: 14 days

07

Study locations

32 of 33 sites recruiting
  • The Children's Hospital Alabama & University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
    • Valerie Tarn · Contactvtarn@uabmc.edu · 2056385134
    • Christopher Fowler, MD · Principal investigator
  • Tucson Cystic Fibrosis Center
    Tucson, Arizona 85713, United States
    Recruiting
  • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
    Los Angeles, California 90027, United States
    Recruiting
    • Ariana Teame, BA · Contactateame@chla.usc.edu
    • Martha McKinney, MD · Principal investigator
  • Stanford University
    Palo Alto, California 94304, United States
    Recruiting
    • Tina Conti, BSRC, RRT, RRT-NPS, C-NPT · Contacttconti@stanford.edu
    • Lori WaiHang Lee, MD · Principal investigator
  • Rady Children's Hospital at University of California San Diego
    San Diego, California 92123, United States
    Not yet recruiting
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Children's Healthcare of Atlanta & Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Joy Dangerfield · Contactjdanger@emory.edu
    • Ajay Kasi, MD · Principal investigator
  • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • Riley Hospital for Children & Indiana University
    Indianapolis, Indiana 46202, United States
    Recruiting
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
  • Johns Hopkins Hospital, Johns Hopkins University
    Baltimore, Maryland 21287, United States
    Recruiting
    • Jamelia Maynard · Contactjmaynar8@jhmi.edu
    • Peter Mogayzel, MD, PhD, MBA · Principal investigator
  • Boston Children's Hospital & Harvard University
    Boston, Massachusetts 02115, United States
    Recruiting
  • University of Michigan Health System
    Ann Arbor, Michigan 48109-5212, United States
    Recruiting
  • Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • The Minnesota Cystic Fibrosis Center & University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Alyssa Perry · Contactahperry@umn.edu
    • Samuel Goldfarb, MD · Principal investigator
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Jana Lomonte · Contactjblomonte@cmh.edu
    • Hugo Escobar, MD · Principal investigator
  • St. Louis Children's Hospital & Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Taylor Haas, RN, BSN · Contactkoenigt@wustl.edu
    • Jessica Pittman, MD · Principal investigator
  • University of Rochester Medical Center Strong Memorial
    Rochester, New York 14642, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Oregon Health & Science University
    Portland, Oregon 97239-3098, United States
    Recruiting
    • Pierce Nusbaum · Contactnusbaum@ohsu.edu
    • Kelvin MacDonald, MD · Principal investigator
  • Children's Hospital of Philadelphia & University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Tyler Johnston, RN · Contactateame@chla.usc.edu
    • Daniel Weiner, MD · Principal investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Anushka Phadke, CRC · Contactphadke@musc.edu · 843-792-4656
    • Sarah Shine, CRC · Contactshinesa@musc.edu · 843-792-1221
    • Sylvia E Szentpeter, MD · Principal investigator
  • University of Texas Southwestern & Children's Health
    Dallas, Texas 75235, United States
    Recruiting
  • Texas Children's Hospital & Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
  • Vermont Children's Hospital & University of Vermont Medical Center
    Burlington, Vermont 05401, United States
    Recruiting
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
    Recruiting
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Recruiting
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
    Recruiting
  • Children's Wisconsin & Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Laura Robertson, CCRC · Contactlrobertson@mcw.edu
    • Nicholas Antos, MD · Principal investigator
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
    Recruiting
  • The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
    Toronto, Ontario M5G 0A4, Canada
    Recruiting
08

References and documents

Publications

  • Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, Rosenfeld M. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Ann Am Thorac Soc. 2023 Dec;20(12):1769-1776. doi: 10.1513/AnnalsATS.202303-245OC. PubMed 37683122 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 23, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Dec 30, 2027
CompletionEst.
Feb 28, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 10 sites. See the sites
Show 10 sites
  • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic · Los Angeles, United StatesContact j•••@chla.usc.edu→a•••@chla.usc.edu
  • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University · Chicago, United StatesContact l•••@luriechildrens.org→l•••@luriechildrens.org · •••2473
  • St. Louis Children's Hospital & Washington University School of Medicine · St Louis, United StatesContact e•••@wustl.edu→k•••@wustl.edu
  • Cincinnati Children's Hospital Medical Center · Cincinnati, United StatesContact s•••@cchmc.org→s•••@cchmc.org
  • Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center · Pittsburgh, United StatesContact a•••@upmc.edu→a•••@chla.usc.edu
  • Medical University of South Carolina · Charleston, United StatesContact s•••@musc.edu→p•••@musc.edu · •••4656Contact added s•••@musc.edu · •••1221
  • Virginia Commonwealth University · Richmond, United StatesContact person changed (no phone or email listed)
  • Seattle Children's Hospital · Seattle, United StatesContact a•••@seattlechildrens.org · •••3317→L•••@seattlechildrens.org · •••3317
  • Children's Wisconsin & Medical College of Wisconsin · Milwaukee, United StatesContact l•••@mcw.edu→l•••@mcw.edu
  • Boston Children's Hospital & Harvard University · Boston, United StatesContact m•••@childrens.harvard.edu→R•••@childrens.harvard.edu
across 2 updates, Nov 9, 2026 – Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Boston Children's Hospital & Harvard University · Boston, United StatesContact m•••@childrens.harvard.edu→R•••@childrens.harvard.edu
  2. Nov 9, 2026
    Site contacts Changed at 9 sites. See the sites
    Show 9 sites
    • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic · Los Angeles, United StatesContact j•••@chla.usc.edu→a•••@chla.usc.edu
    • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University · Chicago, United StatesContact l•••@luriechildrens.org→l•••@luriechildrens.org · •••2473
    • St. Louis Children's Hospital & Washington University School of Medicine · St Louis, United StatesContact e•••@wustl.edu→k•••@wustl.edu
    • Cincinnati Children's Hospital Medical Center · Cincinnati, United StatesContact s•••@cchmc.org→s•••@cchmc.org
    • Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center · Pittsburgh, United StatesContact a•••@upmc.edu→a•••@chla.usc.edu
    • Medical University of South Carolina · Charleston, United StatesContact s•••@musc.edu→p•••@musc.edu · •••4656Contact added s•••@musc.edu · •••1221
    • Virginia Commonwealth University · Richmond, United StatesContact person changed (no phone or email listed)
    • Seattle Children's Hospital · Seattle, United StatesContact a•••@seattlechildrens.org · •••3317→L•••@seattlechildrens.org · •••3317
    • Children's Wisconsin & Medical College of Wisconsin · Milwaukee, United StatesContact l•••@mcw.edu→l•••@mcw.edu
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06654752
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Dec 1, 2024
Primary completion
Dec 30, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Erika Enright
Contact
eenright@uw.edu
206-897-1922
D. B. Sanders, MD, MS
principal investigator · Indiana University
Margaret Rosenfeld, MD, MPH
principal investigator · Seattle Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion